姜黄素
医学
药理学
疾病
糖尿病
内科学
内分泌学
作者
P. Hemachandra Reddy,Maria Mańczak,Xiangling Yin,Mary Catherine Grady,Andrew Mitchell,Sahil Tonk,Chandra Sekhar Kuruva,Jasvinder Singh Bhatti,Ramesh Kandimalla,Murali Vijayan,Subodh Kumar,Rui Wang,Jangampalli Adi Pradeepkiran,Gilbert Ogunmokun,Kavya Thamarai,Kandi Quesada,Annette Boles,Arubala P. Reddy
摘要
The purpose of our article is to assess the current understanding of Indian spice, curcumin, against amyloid-β (Aβ)-induced toxicity in Alzheimer’s disease (AD) pathogenesis. Natural products, such as ginger, curcumin, and gingko biloba have been used as diets and dietary supplements to treat human diseases, including cancer, cardiovascular, respiratory, infectious, diabetes, obesity, metabolic syndromes, and neurological disorders. Products derived from plants are known to have protective effects, including anti-inflammatory, antioxidant, anti-arthritis, pro-healing, and boosting memory cognitive functions. In the last decade, several groups have designed and synthesized curcumin and its derivatives and extensively tested using cell and mouse models of AD. Recent research on Aβ and curcumin has revealed that curcumin prevents Aβ aggregation and crosses the blood-brain barrier, reach brain cells, and protect neurons from various toxic insults of aging and Aβ in humans. Recent research has also reported that curcumin ameliorates cognitive decline and improves synaptic functions in mouse models of AD. Further, recent groups have initiated studies on elderly individuals and patients with AD and the outcome of these studies is currently being assessed. This article highlights the beneficial effects of curcumin on AD. This article also critically assesses the current limitations of curcumin’s bioavailability and urgent need for new formulations to increase its brain levels to treat patients with AD.
科研通智能强力驱动
Strongly Powered by AbleSci AI